Tadalafil for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 4, 2006, Pages 609-617

  Gonzalez, Ricardo R ^a,b   Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Benign prostatic hyperplasia; Erectile dysfunction; Lower urinary tract symptoms; Medical therapy; Nitric oxide; Phosphodiesterases; Sildenafil citrate; Tadalafil

Indexed keywords

PHOSPHODIESTERASE V; PLACEBO; TADALAFIL; CARBOLINE DERIVATIVE; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HUMAN; LOWER URINARY TRACT SYMPTOM; PATHOPHYSIOLOGY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REVIEW; SMOOTH MUSCLE RELAXATION; DRUG INTERACTION; MALE; METABOLISM; URINARY TRACT DISEASE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CARBOLINES; DRUG INTERACTIONS; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROSTATIC HYPERPLASIA; UROLOGIC DISEASES;

EID: 33747829272     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.4.609     Document Type: Review

References (36)

1. ROSEN R, ALTWEIN J, BOYLE P et al.: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. (2003) 44(6):637-649.
2. BERRY SJ, COFFEY DS, WALSH PC, EWING LL: The development of benign prostatic hyperplasia with age. J. Urol. (1984) 132:474-479.
3. MCKINLAY JB: The worldwide prevalence and epidemiology of erectile dysfunction. Int. J. Impot. Res.(2000) 12(Suppl. 4):S6-S11.
4. PEARLMAN CK, KOBASHI LI: Frequency of intercourse in men. J. Urol. (1972) 107:298-301.
5. BRAUN M, WASSMER G, KLOTZ T et al.: Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int. J. Impot. Res. (2000) 12:305-311.
6. GIRMAN CJ, JACOBSEN SJ, RHODES T et al.: Association of health-related quality of life and benign prostatic enlargement. Eur. Urol. (1999) 35:277-284.
7. YASSIN A, SAAD F, HOESL CE et al.: α-Adrenoreceptors are a common denominator in the pathophysilogy of erectile function and BPH/LUTS-implications for clinical practice. Andrologia (2006) 38:1-12.
8. KHAN MA, THOMPSON CS, DASHWOOD MR et al.: Endothelin-1 and nitric oxide in the pathogenesis of urinary tract disorders secondary to bladder outlet obstruction. Curr. Vasc. Pharmacol. (2003) 1(1):27-31.
9. ANDERSSON KE, CHAPPLE CR, HOFNER K: Future drugs for the treatment of benign prostatic hyperplasia. World J. Urol. (2002) 19(6):436-442.
10. GRADINI R, REALACCI M, GINEPRI A et al.: Nitric oxide symhases in normal and benign hyperplastic human prostate: immunohisrochemistry and molecular biology. J. Pathol. (1999) 189(2):224-229.
11. CHITALEY K, WINGARD C, WEBB RC et al.: Antagonism of rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat. Med. (2001) 7:119-122.
12. BING W, CHANG S, HYPOLITE JA et al.: Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am. J. Physiol. Renal Physiol. (2003) 285:F990-F997.
13. CHANG S, HYPOLITE JA, ZDERIC A et al.: Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289:R1124-R1130.
14. DEEDWANIA PC: Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr. Diabetes Rep. (2003) 3:289-292.
15. SCHIFF JD, MULHALL JP: The link between LUTS and ED: clinical and basic science evidence. J. Androl. (2004) 25(4):470-478.
16. CALVERT RC, KHAN MA, THOMPSON CS et al.: Alterations in nitric oxide signaling provides insight into the pathophysiology of erectile dysfunction associated with benign prostatic hyperplasia. Paper presented at: The American Urological Association Annual Meeting. Anaheim, CA, USA (2001).
17. UCKERT S, KUTHE A, JONAS U et al.: Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J. Urol. (2001) 166:2484-2490.
18. BURNETT AL: Nitric oxide control of lower genitourinary tract functions: a review. Urology (1995) 45(6):1071-1083.
19. TAKEDA M, TANG R, SHAPIRO E et al.: Effects of nitric oxide on human and canine prostates. Urology (1995) 45(3):440-446.
20. MOON A: Influence of nitric oxide signalling pathways on pre-contracted human detrusor smooth muscle in vitro. BJU Int. (2002) 89(9):942-949.
21. MCCONNELL JD, ROEHRBORN CG, BAUTISTA AM et al.; for the MTOPS research group: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. (2003) 349(25):2387-2398. The basis for the state-of-the-art medical therapy of BPH.
22. HOPPS CV, MULHALL JP: Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). J. Sex. Med. (2006) (In Press). Early clinical evidence that sildenafil citrate, a PDE5 inhibitor, improves LUTS in men with ED.
23. KAPLAN SA, REIS RB, KOHN IJ et al.: Combination therapy using oral α-blockers and intracavernosal injection in men with erectile dysfunction. Urology (1998) 52(5):739-743.
24. KAPLAN SA. GONZALEZ RR, OGISTE J et al.: Combination of an α-blocker, alfuzosin SR, and a PDE-5 inhibitor, sildenafil citrate, is superior to monotherapy in treating lower urinary tract symptoms (LUTS) and sexual dysfunction. J. Urol. (2006) 175(4):528. Demonstrates a positive synergistic effect by ABs and sildenafil citrate on both LUTS and ED.
25. ROEHRBORN C, MCVARY K, KAMINETSKY J et al.: The efficacy and safety of tadalafil administered once a day for lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). J. Urol. (2006) 175(4):527. Randomised, controlled trial of tadalafil versus placebo in treating LUTS and ED.
26. ANGULO J, GADAU M, FERNANDEZ A et al.: IC-351 enhances nitric oxide-mediated relaxation of human arterial and trabecular penile smooth muscle. Diabetologia (2001) 44(Suppl. 1):A295.
27. CURRAN MP, KEATING GM: Tadalafil. Drugs (2003) 63(20):2203-2212.
28. MEULEMAN EJH: Review of tadalafil in the treatment of erectile dysfunction. Expert Opin. Pharmacotber. (2003) 4(11):2049-2056. A thorough review of tadalafil for the treatment of ED.
29. PATTERSON B, BEDDING A, JEWELL H et al.: Dose-normalised pharmacokinetics of tadalafil administered as a single dose to healthy volunteers. Eur. Urol. (2002) 41(Suppl. 1):152.
30. PORST H: IC-351 (tadalafil, Cialis): update on clinical experience. Int. J. Impot. Res. (2002) 14(Suppl. 1):S57-S64.
31. PATTERSON B, BEDDING A, JEWELL H et al.: The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC-351). Presented at: The European Society for Sexual and Impotence Research. Rome, Italy (2001).
32. HUTTER AM, KLONER RA, WATKINS versus et al.: Poster, presented at: The 17th Annual Scientific Meeting of the American Society of Hypertension (ASH). New York, NY, USA (2002).
33. KLONER RA: Pharmacology and drug interaction effects of phosphodiesterase 5 inhibitors: focus on α-blocker interactions. Am. J. Cardiol. (2005) 96(12B):42M-46M. Thorough review of α-blocker and PDE5 inhibitor cardiovascular interactions.
34. KLONER RA, JACKSON G, EMMICK JT et al.: Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 α-blockers, doxazosin and tamsulosin in healthy normotensive men. J. Urol. (2004) 172(5Pt 1):1935-1940.
35. HELLSTROM W, OVERSTREET JW, YU A et al.: Tadalafil has no effect on spermatogenesis or reproductive hormones. J. Urol. (2003) 169(Suppl. 4):245.
36. HAYREH SS: Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? J. Neuroophthalmol. (2005) 25(4):295-298.